FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis. Regulatory decision expected 1st quarter 2027. Supported by phase 3 RCTs, 3000 pts -- LATITUDE PsO 3001 and 3002 clinical trials. https://t.co/o7oqxSXHSw https://t.co/evzPtaTWI4
Links:
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis | Patient Care O…
https://buff.ly/z1hbis4
Sep-14-2026
